Status:
UNKNOWN
Effectiveness of Intracoronary Injection of Eptifibatide in Primary Coronary Intervention in STEMI Patients
Lead Sponsor:
Assaf-Harofeh Medical Center
Conditions:
Acute Myocardial Infarction
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
Brief Summary
The achievement of high local concentration of Eptifibatide, a GP 2b3a inhibitor,via direct intracoronary injection, promotes (in vitro) clot disaggregation. It remains unclear if it is of superior be...
Detailed Description
Patients will be randomized, prospectively, single blinded into one of two arms:1)intravenous administration of Eptifibatide and 2) intracoronary administration. The primary end-point will be the angi...
Eligibility Criteria
Inclusion
- Acute myocardial infarction candidate for primary coronary angioplasty, presenting within 12 hours of onset of pain and ability to clearly identified only one infarct related artery.
Exclusion
- Contraindications for antiplatelet therapy such as bleeding disorders,
- Thrombocytopenia,
- Severe uncontrolled hypertension,
- Recent stroke (\<6 months),
- Intracranial hemorrhage at any time
- Patients after recent major surgery (\<30 days),
- Previous myocardial infarction
- Previous revascularization either by CABG or PCI and 9)patients presented with cardiogenic shock.
Key Trial Info
Start Date :
August 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
February 1 2010
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT00945308
Start Date
August 1 2009
End Date
February 1 2010
Last Update
July 24 2009
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assaf Harofeh Medical Center
Beer Yakov, Beer Yakov, Israel, 70300